Highlights Medigene AG

Equities

MDG1

DE000A1X3W00

Market Closed - Xetra Other stock markets 16:36:13 24/06/2024 BST			5-day change	1st Jan Change
1.175 ^EUR	-3.29%		-6.37%	-22.95%

05-21	Medigene, BioNTech Extend Cancer Immunotherapy Partnership	MT
05-21	Medigene AG's Global Research & Collaboration Agreement with BioNTech SE to Extend Beyond Initial Announced Term	CI

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Medigene, BioNTech Extend Cancer Immunotherapy Partnership	05-21	MT
Medigene AG's Global Research & Collaboration Agreement with BioNTech SE to Extend Beyond Initial Announced Term	05-21	CI
Medigene AG Presents Preclinical Data on Optimal Affinity TCRs Targeting the Neoantigen Mutant KRAS	05-15	CI
Medigene Ag Maintains Earnings Guidance for 2024	05-14	CI
Medigene AG Expands Patent Portfolio with European Patent Grant for its NY-ESO-1 - Targeted T Cell Receptor	05-02	CI
Medigene Presents Superior TCR-T Cell Functionality by Inclusion of A Costimulatory Switch Protein	05-02	CI
Medigene AG Presents Streamlined 6-Day, High Stemness Tcr-T Therapy Production Process	04-25	CI
Rights Issue: 1 new share @ 1.2 EUR for 5 existing shares	04-23	FA
Medigene AG Presents Favorable Safety Profile of TCR-T Cells with Costimulatory Switch Protein at AACR Annual Meeting 2024	04-08	CI
Medigene Gets European Patent for T-Cell Receptor Technology	04-04	MT
Medigene AG Secures European Patent for Its iM-TCR Technology	04-04	CI
Medigene AG Reports Earnings Results for the Full Year Ended December 31, 2023	03-29	CI
Medigene Ag Provides Earnings Guidance for 2024	03-28	CI
Medigene AG Expands Patent Portfolio in Japan for iM-TCR Technology to Directly Control TCR-T Safety and Efficacy	03-04	CI
Medigene AG Announces Indication Selection for the Clinical Development of Its Lead 3Rd Generation Tcr-T Therapy Program in Solid Tumors	02-12	CI
Medigene AG Maintains Financial Guidance for the Fiscal Year 2023	11-21	CI
Medigene Presents New Data for MDG 2011, the First TCR in a Novel Kras Library	11-04	CI
Medigene AG Presents First Pre-Clinical Data of Optimal Affinity TCR Targeting mKRAS G12V Combined with a PD1-41BB Costimulatory Switch Protein Showing	23/10/23	CI
Medigene to Present New Pre-Clinical Data for Pipeline TCR-T Therapies At the ESMO Congress 2023	16/10/23	CI
Medigene Expands Intellectual Property Rights for its Costimulatory Switch Proteins to Additional Immune Cell Types	23/08/23	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Medigene AG

Equities

MDG1

DE000A1X3W00

Highlights

Filters